Pediatric Neurology
Volume 41, Issue 6 , Pages 435-439 , December 2009

Metabolic Alterations During Valproic Acid Treatment: A Prospective Study

  • Ayhan Abaci, MD

      Affiliations

    • Division of Endocrinology, Department of Pediatrics, Faculty of Medicine, Dokuz Eylül University, Izmir, Turkey
    • ,
  • Murat Saygi, MD

      Affiliations

    • Division of Endocrinology, Department of Pediatrics, Faculty of Medicine, Dokuz Eylül University, Izmir, Turkey
    • ,
  • Uluc Yis, MD

      Affiliations

    • Division of Neurology, Department of Pediatrics, Faculty of Medicine, Dokuz Eylül University, Izmir, Turkey
    • ,
  • Korcan Demir, MD

      Affiliations

    • Division of Endocrinology, Department of Pediatrics, Faculty of Medicine, Dokuz Eylül University, Izmir, Turkey
    • ,
  • Eray Dirik, MD

      Affiliations

    • Division of Neurology, Department of Pediatrics, Faculty of Medicine, Dokuz Eylül University, Izmir, Turkey
    • ,
  • Ece Bober, MD

      Affiliations

    • Division of Endocrinology, Department of Pediatrics, Faculty of Medicine, Dokuz Eylül University, Izmir, Turkey
    • Corresponding Author InformationCommunications should be addressed to: Dr. Bober; Division of Endocrinology, Department of Pediatrics; Faculty of Medicine, Dokuz Eylül University; 35340 Inciralti, Izmir, Turkey.

Received 7 January 2009 ,Accepted 23 June 2009.

References 

  1. Davis R, Peters DH, McTavish D. Valproic acid. A reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs. 1994;47:332–372
  2. Freitag FG, Collins SD, Carlson HA, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology. 2002;58:1652–1659
  3. Ghaemi SN, Gilmer WS, Goldberg JF, et al. Divalproex in the treatment of acute bipolar depression: A preliminary double-blind, randomized, placebo-controlled pilot study. J Clin Psychiatry. 2007;68:1840–1844
  4. Biton V. Effect of antiepileptic drugs on bodyweight: Overview and clinical implications for the treatment of epilepsy. CNS Drugs. 2003;17:781–791
  5. Easter D, O'Bryan-Tear CG, Verity C. Weight gain with valproate or carbamazepine—A reappraisal. Seizure. 1997;6:121–125
  6. Verity CM, Hosking G, Easter DJ. A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy. The Paediatric EPITEG Collaborative Group. Dev Med Child Neurol. 1995;37:97–108
  7. Egger J, Brett EM. Effects of sodium valproate in 100 children with special reference to weight. Br Med J [Clin Res]. 1981;283:577–581
  8. Grosso S, Mostardini R, Piccini B, Balestri P. Body mass index and serum lipid changes during treatment with valproic acid in children with epilepsy. Ann Pharmacother. 2009;43:45–50
  9. Verrotti A, Scardapane A, Franzoni E, Manco R, Chiarelli F. Increased oxidative stress in epileptic children treated with valproic acid. Epilepsy Res. 2008;78:171–177
  10. Wirrell EC. Valproic acid-associated weight gain in older children and teens with epilepsy. Pediatr Neurol. 2003;28:126–129
  11. Corman CL, Leung NM, Guberman AH. Weight gain in epileptic patients during treatment with valproic acid: A retrospective study. Can J Neurol Sci. 1997;24:240–244
  12. Dinesen H, Gram L, Andersen T, Dam M. Weight gain during treatment with valproate. Acta Neurol Scand. 1984;70:65–69
  13. Isojarvi JI, Laatikainen TJ, Knip M, Pakarinen AJ, Juntunen KT, Myllyla VV. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol. 1996;39:579–584
  14. Aydin K, Serdaroglu A, Okuyaz C, Bideci A, Gucuyener K. Serum insulin, leptin, and neuropeptide Y levels in epileptic children treated with valproate. J Child Neurol. 2005;20:848–851
  15. Tan H, Orbak Z, Kantarci M, Kocak N, Karaca L. Valproate-induced insulin resistance in prepubertal girls with epilepsy. J Pediatr Endocrinol Metab. 2005;18:985–989
  16. Hamed SA, Fida NM, Hamed EA. States of serum leptin and insulin in children with epilepsy: Risk predictors of weight gain. Eur J Paediatr Neurol. 2009;13:261–268
  17. Pylvanen V, Knip M, Pakarinen AJ, et al. Fasting serum insulin and lipid levels in men with epilepsy. Neurology. 2003;60:571–574
  18. Pylvanen V, Pakarinen A, Knip M, Isojarvi J. Characterization of insulin secretion in valproate-treated patients with epilepsy. Epilepsia. 2006;47:1460–1464
  19. Isojarvi J. Disorders of reproduction in patients with epilepsy: Antiepileptic drug related mechanisms. Seizure. 2008;17:111–119
  20. Roste LS, Tauboll E, Morkrid L, et al. Antiepileptic drugs alter reproductive endocrine hormones in men with epilepsy. Eur J Neurol. 2005;12:118–124
  21. Bauer J, Cooper-Mahkorn D. Reproductive dysfunction in women with epilepsy: Menstrual cycle abnormalities, fertility, and polycystic ovary syndrome. Int Rev Neurobiol. 2008;83:135–155
  22. Isojarvi JI, Tapanainen JS. Valproate, hyperandrogenism, and polycystic ovaries: A report of 3 cases. Arch Neurol. 2000;57:1064–1068
  23. Lofgren E, Mikkonen K, Tolonen U, et al. Reproductive endocrine function in women with epilepsy: The role of epilepsy type and medication. Epilepsy Behav. 2007;10:77–83
  24. Balaguer Martinez JV, Lopez Garcia MJ, Andres CM, Contell VA, Castello Pomares ML. Effects of valproate on sexual development. An Pediatr (Barc). 2003;58:443–448
  25. De VL, Karasik A, Landau Z, Phillip M, Kiviti S, Goldberg-Stern H. Endocrine effects of valproate in adolescent girls with epilepsy. Epilepsia. 2007;48:470–477
  26. National Center for Health Statistics. CDC growth charts: United States. 2002. Available from http://www.cdc.gov/nchs/about/major/nhanes/growthcharts/datafiles.htm.
  27. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. Br Med J [Clin Res]. 2000;320:1240–1243
  28. Valerio G, Licenziati MR, Iannuzzi A, et al. Insulin resistance and impaired glucose tolerance in obese children and adolescents from southern Italy. Nutr Metab Cardiovasc Dis. 2006;16:279–284
  29. American Academy of Pediatrics. National Cholesterol Education Program: Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics. 1992;89:525–584
  30. Genuth S, Alberti KG, Bennett P, et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care. 2003;26:3160–3167
  31. Cleophas TJ, Zwinderman AH, Cleophas TF, Cleophas EP. Controlling the risk of false positive clinical trials. In:  Cleophas TJ,  Zwinderman AH,  Cleophas TF,  Cleophas EP editor. Statistics applied to clinical trials. 4th ed. Dordrecht: Springer; 2009;p. 107–111
  32. Jallon P, Picard F. Bodyweight gain and anticonvulsants: A comparative review. Drug Saf. 2001;24:969–978
  33. Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell. 2001;104:531–543
  34. Biton V, Mirza W, Montouris G, Vuong A, Hammer AE, Barrett PS. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology. 2001;56:172–177
  35. Novak GP, Maytal J, Alshansky A, Eviatar L, Sy-Kho R, Siddique Q. Risk of excessive weight gain in epileptic children treated with valproate. J Child Neurol. 1999;14:490–495
  36. Verrotti A, Basciani F, De SM, Trotta D, Morgese G, Chiarelli F. Insulin resistance in epileptic girls who gain weight after therapy with valproic acid. J Child Neurol. 2002;17:265–268
  37. Luef G, Abraham I, Hoppichler F, et al. Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy. Metabolism. 2002;51:1274–1278
  38. Pylvanen V, Knip M, Pakarinen A, Kotila M, Turkka J, Isojarvi JI. Serum insulin and leptin levels in valproate-associated obesity. Epilepsia. 2002;43:514–517
  39. Vorum H, Gram L, Honore B. Valproate and palmitate binding to serum albumin in valproate-treated patients. Relation to obesity. Epilepsy Res. 1993;16:55–64
  40. Stephen LJ, Kwan P, Shapiro D, Dominiczak M, Brodie MJ. Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy. Epilepsia. 2001;42:1002–1006
  41. Morrell MJ, Isojärvi J, Taylor AE, et al. Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy. Epilepsy Res. 2003;54:189–199
  42. Morrell MJ, Hayes FJ, Sluss PM, et al. Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine. Ann Neurol. 2008;64:200–211
  43. Vainionpää LK, Rättyä J, Knip M, et al. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann Neurol. 1999;45:444–450
  44. Mikkonen K, Vainionpää LK, Pakarinen AJ, et al. Long-term reproductive endocrine health in young women with epilepsy during puberty. Neurology. 2004;62:445–450
  45. Eiris J, Novo-Rodriguez MI, Del RM, Meseguer P, Del Rio MC, Castro-Gago M. The effects on lipid and apolipoprotein serum levels of long-term carbamazepine, valproic acid and phenobarbital therapy in children with epilepsy. Epilepsy Res. 2000;41:1–7
  46. Sonmez FM, Demir E, Orem A, et al. Effect of antiepileptic drugs on plasma lipids, lipoprotein (a), and liver enzymes. J Child Neurol. 2006;21:70–74
  47. Yilmaz E, Dosan Y, Gurgoze MK, Gungor S. Serum lipid changes during anticonvulsive treatment serum lipids in epileptic children. Acta Neurol Belg. 2001;101:217–220
  48. Yalcin E, Hassanzadeh A, Mawlud K. The effects of long-term anticonvulsive treatment on serum lipid profile. Acta Paediatr Jpn. 1997;39:342–345
  49. Calandre EP, Rodriquez-Lopez C, Blazquez A, Cano D. Serum lipids, lipoproteins and apolipoproteins A and B in epileptic patients treated with valproic acid, carbamazepine or phenobarbital. Acta Neurol Scand. 1991;83:250–253
  50. Demircioglu S, Soylu A, Dirik E. Carbamazepine and valproic acid: Effects on the serum lipids and liver functions in children. Pediatr Neurol. 2000;23:142–146
  51. Verrotti A, Domizio S, Angelozzi B, Sabatino G, Morgese G, Chiarelli F. Changes in serum lipids and lipoproteins in epileptic children treated with anticonvulsants. J Paediatr Child Health. 1997;33:242–245
  52. Voudris KA, Attilakos A, Katsarou E, et al. Early and persistent increase in serum lipoprotein (a) concentrations in epileptic children treated with carbamazepine and sodium valproate monotherapy. Epilepsy Res. 2006;70:211–217

PII: S0887-8994(09)00346-4

doi: 10.1016/j.pediatrneurol.2009.06.003

Pediatric Neurology
Volume 41, Issue 6 , Pages 435-439 , December 2009

Article Tools